“A REVIEW ON HERBAL SURFACTANT”

A Project Report
Submitted To

RAJASTHAN UNIVERSITY OF HEALTH SCIENCE, JAIPUR (RAJ.)

In the partial fulfillment of the requirements for the award of the degree of
BACHELOR OF PHARMACY
Submitted by

Mr. /Ms. Ankit kumar, Avni Sharma, Dheeraj Kumar, Himanshu Khatri,
Himen Soni, Ranjeet Kumar.
Supervised by

Ms. Nikita Kumawat

Associate Professor
SUNRISE COLLEGE OF PHARMACY
Nr. Bari Mata temple, Umarda, Udaipur
(Affiliated to RUHS, Jaipur & Approved by PCI, New Delhi)

ESTD-2020
SUNRISE COLLEGE OF PHARMACY, UDAIPUR
 2020-2021
Sunrise College of Pharmacy
Nr. Bari mata temple, Umarda, Udaipur
( Approved by PCI, New Delhi & Affiliated to RUHS, Jaipur)

DECLARATION

I hereby declare that a project report entitled “Neurodegenerative disease (A

Progressive disorder)” has been carried out by me under the guidance and
supervision of Ms. Nikita Kumawat, Assistant Professor, Sunrise College of
Pharmacy, Udaipur (Raj.) for the partial fulfillment of requirement for the
Awarded degree of Bachelor of Pharmacy.

I further declare that, this work is the result of my own investigation, except where
otherwise stated and that neither any part of this thesis nor the whole of the project
report has been submitted for the award of any other degree, diploma associate
ship and fellowship any other similar title.

NAME: - Mr/Ms. Himanshu Khatri, Ankit Kumar,

Avni Sharma, Himen Soni, Ranjeet
Kumar.

ii
 Sunrise College of Pharmacy
Nr. Bari mata temple, Umarda, Udaipur
( Approved by PCI, New Delhi & Affiliated to RUHS, Jaipur)

CERTIFICATE
I hereby declare that this project report entitled “Neurodegenerative Disease (A
Progressive Disorder)” original work carried out by original work carried out by
Ankit kumar, Avni Sharma, Dheeraj Kumar, Himanshu Khatri, Himen Soni,
Ranjeet Kumar. under my guidance in the Department of Pharmaceutical
Chemistry of partial fulfillment for the award of the Degree of Bachelor of
Pharmacy in Sunrise College of Pharmacy, Udaipur. (Raj).

I further declare that the work reported here in does not from part of any other
thesis or dissertation on the basis of which a degree or award was conferred on an
earlier occasion of thesis of any other candidate.

Date:13/1/2025
Supervised By: Forwarded by:
Ms. Seema Wadhwani Dr. R. S. Bhadauria
Associate Professor Principal
Sunrise College of Pharmacy, Sunrise College of Pharmacy,
Udaipur (Raj.) Udaipur (Raj.)

iii
 Sunrise College of Pharmacy
Nr. Bari mata temple, Umarda, Udaipur
( Approved by PCI, New Delhi & Affiliated to RUHS, Jaipur )

FORWARDING LETTER

Mr./Ms. Ankit Kumar, Avni Sharma, Dheeraj Kumar, Himanshu Khatri,

Himen Soni, Ranjeet Kumar has completed his project report entitled
“Neurodegenerative Disease (A progressive disorder)” under the supervision
of Ms. Nikita Kumawat of partial fulfillment for the award of the Degree of
Bachelor of Pharmacy in Sunrise College of Pharmacy, Udaipur (Raj).

Date:13/1/2025

Forwarded by:
Dr. Raghvendra Singh Bhadauria
Principal
Sunrise College of Pharmacy, Udaipur

iv
 ACKNOWLEDGMENT
Climbing to the top demands strength, whether it is to the
top of Mount Everest or to the top of your career
-A P J ABDUL KALAM
My efforts through this project report by many people, directly or indirectly, and
I would like to take this opportunity to thank them all for their assistance. I
consider myself most lucky to work under the kind guidance Ms. Nikita Kumawat.
I take this opportunity to express my heartfelt gratitude to my reverend guide, his
discipline, principal, simplicity caring attitude and provision of fearless work
environment will be cherished in all walk of my life. I am very much grateful to
him for his invaluable guidance and everlasting encouragement throughout my
course.
I owe my warmest and humble thanks to pharmacy faculty, All Teaching Staff
their timely help, encouragement and boosting my confidence in the progress of
my academics.
I would thank all non-teaching staff of my college for their timely help
whenever needed.
Most important I want to thanks God my soul ruler for always supporting
me in the right direction in my life and giving me strength to stand in the worst
situation of my life and covering me under his shadow of love and care.
I express my deepest and special thanks to my batch mates and my parents
for their kind cooperation and encouragement through my graduation.

Name: -Ankit kumar, Avni Sharma, Dheeraj

Kumar, Himanshu Khatri, Himen Soni, Ranjeet Kumar.

v
 CONTENT

Sr. No Topic Pg. No.

1. INTRODUCTION 1-7

2. ALZHEIMER'S DISEASE 8-11

3. PARKINSON'S DISEASE 12-23

4. AMYOTROPHIC LATERAL SCLEROSIS 24-32

5. AYURVEDIC TREATMENT OF NEURODEGENERATIVE 33-36

DISEASE

6. HOMEOPATHIC TREATMENT OF
NEURODEGENERATIVE DISEASE

7 CONCLUSION

vi
8 REFERENCES

vii
[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER -1
INTRODUCTION

Sunrise College of Pharmacy, Udaipur Page 1

CHAPTER-1
INTRODUCTION: -

1.1 INTRODUCTION1-6: -

Neurodegenerative diseases are conditions that gradually damage and destroy parts of your
nervous system, especially areas of your brain. These conditions usually develop slowly, and
the effects and symptoms tend to appear later in life.

Neurodegenerative diseases pose a major global health challenge, with no effective treatments
to prevent or halt their progression. Key pathological processes include protein misfolding,
mitochondrial dysfunction, neuroinflammation, and transsynaptic spread of toxic proteins.
Aging is a significant risk factor, making neurons highly vulnerable to homeostatic disruptions.
Transgenic animal models aid in understanding disease mechanisms and testing potential
therapeutics. Advances in diagnostics are crucial for early detection and intervention. While
challenges remain, continued research into diverse targets offers hope for effective treatments
in the future.

A neurodegenerative disease is caused by the progressive loss of neurons, in the process known
as neurodegeneration.

This term does not just refer to a single type of condition. Instead, it is an umbrella term that
applies to several types of conditions.

Neuronal damage may also ultimately result in their death.

Neurodegeneration can be found in the brain at many distinct levels of neuronal circuitry,
ranging from molecular to systemic. Because there is no known way to reverse the progressive
degeneration of neurons, these diseases are considered to be incurable; however, research has
shown that the two major contributing factors to neurodegeneration are oxidative stress and
inflammation.1

Sunrise College of Pharmacy, Udaipur Page 2

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

1.2 TYPES OF NEURODEGENERATIVE DISEASES: -

• Amyotrophic Lateral Sclerosis

• multiple sclerosis

• Parkinson's disease

• Alzheimer's disease

• Huntington's disease

• multiple system atrophy

• tauopathies

• prion diseases 2

1.3 The global distribution of the disease burden:-

In 2019, around 50 million people worldwide had a neurodegenerative disease, often leading
to dementia. This number is expected to rise to 152 million by 2060. In Europe, the prevalence
of dementia increases with age, affecting about 1.6% of males and 1% of females aged 65-69,
and rising to 11% and 12.6% in those aged 85-89.

Among different types of dementia, Alzheimer’s disease (AD) is the most common (62% of
cases), followed by vascular dementia (VaD) (17%), a mix of AD and VaD (10%), dementia
with Lewy bodies (4%), frontotemporal dementia (FTD) (2%), and Parkinson’s disease
dementia (PDD) (2%). Other causes make up 3% of cases.

1.4 Causes neurodegenerative diseases: -

Some neurodegenerative diseases have a single cause that healthcare providers can identify.
But in many cases, there isn’t a single cause. Instead, research shows multiple factors contribute
to neurodegenerative diseases. And there are times when providers might not be able to find a
cause — which can be frustrating for someone with one of these conditions or their loved ones.

So far, experts have identified dozens of probable causes or risk factors. These tend to fall into
a few specific categories, including:

• Age: This is the most crucial factor in developing neurodegenerative diseases. These
conditions have strong ties to age. The older you are, the greater your chances of

Sunrise College of Pharmacy, Udaipur Page 3

 developing one. Some degenerative brain diseases can start earlier in life, but this is
less common.

• Genetics: Many neurodegenerative diseases have strong ties to family history. That is
often because of specific mutations you can inherit that increase your risk. Spontaneous
mutations can also happen, and sometimes a combination of genes plays a role.

• Environment: Your environment can be a major factor in developing these conditions.

Exposure to pollution, chemicals and toxins, certain types of infections and even where
you live may all play a role (for example, lower vitamin D levels, which are more
common the farther you live from the Earth’s equator, have links to dementia-type
diseases).

• Medical history: Your medical history and past health events can all play a role in
developing neurodegenerative diseases. Some neurodegenerative conditions can either
happen because of specific medical events or can get worse because of them. Some
examples include cancer, certain types of infections, if you have had head injuries and
more.

• Habits, routine and choices: Examples include what you eat, how active you are,
whether you use tobacco products, how much alcohol you consume and many more.

• Several cellular mechanisms are implicated in neurodegeneration:

1. Protein Misfolding and Aggregation: Abnormal folding and accumulation of proteins,

such as amyloid-beta in Alzheimer's and alpha-synuclein in Parkinson's, are hallmarks
of many neurodegenerative disorders.

2. Oxidative Stress: An imbalance between the production of reactive oxygen species

(ROS) and the body's ability to detoxify them leads to oxidative stress, which damages
neurons.

3. Mitochondrial Dysfunction: Mitochondria, the energy-producing organelles in cells,

can become dysfunctional in neurodegenerative disorders, leading to cell death.

4. Neuroinflammation: Chronic inflammation in the brain, driven by activated microglia

and astrocytes, contributes to neuronal damage and degeneration. 3-4

Sunrise College of Pharmacy, Udaipur Page 4

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

1.5 Symptoms of Neurodegenerative Disorders

Neurodegenerative disorders present with a wide range of symptoms that vary depending on
the specific disease and the affected brain regions.

1. Cognitive Symptoms

a. Memory loss

b. Difficulty concentrating

c. Confusion

d. Impaired judgment

2. Motor Symptoms

a. Tremors

b. Muscle stiffness

c. Slowness of movement (bradykinesia)

d. Loss of coordination and balance

3. Psychiatric Symptoms

a. Depression

b. Anxiety

c. Mood swings

d. Behavioral changes 5-6

NOTE: - Specific disease has their specific symptoms.

1.6 Diagnosis of Neurodegenerative Disorders

Diagnosing neurodegenerative disorders involves a combination of clinical evaluation,

neurological examinations, and advanced diagnostic tests.

Clinical Evaluation

A thorough medical history and physical examination are essential first steps in diagnosing
neurodegenerative disorders. Physicians assess the patient's symptoms, family history, and any
potential environmental exposures.

Sunrise College of Pharmacy, Udaipur Page 5

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Neurological Examinations

Neurological examinations help evaluate the patient's cognitive and motor functions. Tests may
include assessments of memory, language skills, reflexes, muscle strength, coordination, and
gait.

Advanced Diagnostic Tests

Imaging Techniques: Magnetic resonance imaging (MRI) and positron emission tomography
(PET) scans provide detailed images of the brain, helping to identify structural abnormalities
and patterns of brain activity.

Biomarker Analysis: Analyzing cerebrospinal fluid (CSF) for specific biomarkers, such as
amyloid-beta and tau proteins in Alzheimer's disease, can aid in diagnosis.

Genetic Testing: Genetic testing can identify mutations associated with certain
neurodegenerative disorders, such as the HTT gene in Huntington's disease. 7

1.7 Treatments for Neurodegenerative Disorders

While there is currently no cure for neurodegenerative disorders, several treatment strategies
aim to manage symptoms, slow disease progression, and improve the quality of life for patients.

Medications

Cholinesterase Inhibitors: Used in Alzheimer's disease to improve cognitive function by

increasing levels of acetylcholine in the brain.

Dopaminergic Medications: Used in Parkinson's disease to replenish dopamine levels and

alleviate motor symptoms.

Antidepressants and Antipsychotics: Used to manage psychiatric symptoms in various

neurodegenerative disorders.

Non-Pharmacological Interventions

Physical Therapy: Helps maintain mobility, balance, and muscle strength.

Occupational Therapy: Assists patients in adapting to daily activities and improving their
quality of life.

Speech Therapy: Addresses speech and swallowing difficulties.

Sunrise College of Pharmacy, Udaipur Page 6

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Lifestyle Modifications

Diet and Nutrition: A healthy diet rich in antioxidants and anti-inflammatory foods may support
brain health.

Exercise: Regular physical activity has been shown to have neuroprotective effects and improve
overall well-being.

Cognitive Stimulation: Engaging in mentally stimulating activities, such as puzzles and

reading, may help preserve cognitive function.

Emerging Therapies

• Research into novel treatments for neurodegenerative disorders is ongoing, with several
promising approaches under investigation.

• Gene Therapy: Aims to correct genetic mutations or deliver therapeutic genes to

affected cells.

• Stem Cell Therapy: Involves the transplantation of stem cells to replace damaged
neurons and promote tissue repair.

• Immunotherapy: Targets misfolded proteins and neuroinflammation using antibodies

or vaccines. 8-9

1.7 Prevention: -

Can this be prevented?

Neurodegenerative diseases happen unpredictably. Most of them happen for reasons that aren’t
fully understood. Because of both those facts, they aren’t preventable.

How can I lower my risk?

While neurodegenerative diseases aren’t preventable, there are things you can do to lower your
risk of developing one. Because these diseases are often due to a combination of factors,
reducing the number of factors may help lower your risk.

Steps you can take to reduce your risk include:

• Eat a balanced diet. Your diet affects your brain health. A poor diet can make your
brain more vulnerable to developing a neurodegenerative disorder. It can also make
other conditions that could contribute (such as stroke) more likely to happen.

Sunrise College of Pharmacy, Udaipur Page 7

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Stay physically active and maintain a healthy weight. Your weight and activity level
also affect your brain. Weight-related conditions and concerns, especially circulatory
problems like high blood pressure and metabolic conditions like Type 2 diabetes, can
also contribute.

• Wear safety equipment as needed. Head injuries, especially concussions and

traumatic brain injuries, can strongly increase your risk of a neurodegenerative disorder.
That makes safety equipment invaluable to preventing injury and protecting your brain
health in the long run.

• See your primary care provider annually. This can help avoid or delay chronic
medical conditions that might later contribute to neurodegenerative diseases. These
visits may also help detect neurodegenerative diseases earlier. That’s helpful because
many of these conditions are much more treatable in their earlier stages. 10-11

Sunrise College of Pharmacy, Udaipur Page 8

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER -2
ALZHEIMER'S DISEASE

Sunrise College of Pharmacy, Udaipur Page 9

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER -2

ALZHEIMER'S DISEASE

2.1 Introduction:-

Alzheimer's disease is the leading cause of dementia. Recent research has helped us understand
the disease better, especially the two main features: plaques made of amyloid β (Aβ) and tangles
made of a protein called tau that is over-phosphorylated. While we know more about the
disease, we also realize that it is more complicated than we first thought. Familial Alzheimer's
disease is rare and occurs early in life due to gene mutations related to Aβ production. On the
other hand, sporadic Alzheimer's disease is much more common, affecting over 15 million
people around the world.12

Alzheimer’s disease is a progressive and irreversible brain condition. The two most common
symptoms of the condition are confusion and memory loss. Alzheimer's disease slowly causes
thinking and memory to deteriorate to the point that even simple tasks become difficult or
impossible.

Alzheimer’s disease can eventually cause a person to lose their ability to respond to their
environment, including becoming unable to carry out a conversation.

It is also the most common cause of dementia in older adults. The Alzheimer's Association
suggests that somewhere between 60% and 80% of dementia is caused by Alzheimer's disease.

Alzheimer's Association. What is Alzheimer's disease?

According to the Centers for Disease Control and Prevention (CDC), Alzheimer's disease is the
sixth leading cause of death for adults over the age of 65.13

While there is no cure for Alzheimer's, there are treatments available that can help slow the
disease's progression, making early detection important. Behavioral and medication treatments
can also help people cope with the symptoms of the disease.

Reasons for this failure rate include inappropriate drug doses, invalid target and participant
selection, and inadequate knowledge of the pathophysiology of AD.

Currently, diagnoses of Alzheimer's are subpar, and better methods need to be utilized for
various aspects of clinical diagnoses.

Sunrise College of Pharmacy, Udaipur Page 10

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

2.2 Symptoms: -

The most common symptom that people begin to notice is difficulty remembering new
information. This symptom may be subtle initially, and people may dismiss it as normal
forgetting or normal age-related memory decline.

Because of the progressive nature of Alzheimer's disease, this forgetting will eventually
become more pronounced. People may also begin to exhibit more severe memory problems as
well as other symptoms, including:

• Behavioral and personality changes

• Confusion

• Difficulty speaking

• Difficulty with multi-step tasks

• Disorientation

• Mood changes

• Problems remembering events, time, and places

• Unfounded suspicions

• Repeating questions

• Sleeping difficulties

• Swallowing problems

• Trouble recognizing family and friends

Sunrise College of Pharmacy, Udaipur Page 11

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Trouble walking

• Wandering or getting lost

2.3 Stages:-

While symptoms can vary from person to person, the progression of the disease usually
follows a pattern that can be broken down into three general stages.

2.3.1 Early Stage:-

During this early stage of the disease, people begin to experience mild symptoms but often
still function and live independently. While they continue to live their lives, including doing
things like socializing and working, they may have memory lapses that make it difficult to
remember words, names, and the locations of everyday things.

Some symptoms that a person might experience at this point include:

• Difficulty with organizing and planning

• Difficulty remembering appointments

• Forgetting the sequence of steps needed to complete a task

• Forgetting recent conversations or recently learned information

• Losing or misplacing things

• Trouble remembering the right word to describe something

• Trouble judging how much time is needed to finish a task

2.3.2 Middle Stage:-

This stage of the disease is usually the longest. During this time, symptoms grow
progressively worse, and memories, including long-term memories, begin to decline.

Behavioral and emotional changes are also common. People may experience frustration,
anxiety, and agitation. It becomes increasingly difficult for people to function, and they
depend on others to help with daily tasks.

People at the moderate stage of Alzheimer's disease display symptoms such as:

• Difficulty with some normal daily activities, including self-care

• Increased confusion

Sunrise College of Pharmacy, Udaipur Page 12

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Increased memory loss

• May exhibit suspicions of friends and family or delusions

• Poor judgment

2.3.3 Late Stage:-

During the late stages of the disease, mental function declines to the point that it has a serious
impact on physical functioning. At this point, people lose various aspects of motor functioning
and the ability to converse. They require around-the-clock care and assistance.

Symptoms at this stage include:

• Difficulty or inability to walk without assistance

• Difficulty or inability to swallow

• Loss of awareness of their surroundings

• May become unable to sit up or hold their head up without assistance

• Unable to control bladder and bowel functions13

Sunrise College of Pharmacy, Udaipur Page 13

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

2.4.1 Causes: -

• The Cholinergic Hypothesis suggests that Alzheimer's disease (AD) is linked to a

decline in acetylcholine (ACh), a key neurotransmitter for memory and learning. This
happens due to damage in cholinergic neurons and reduced enzyme activity needed for
ACh production. β-amyloid (Aβ) disrupts cholinergic signaling, leading to memory
loss.
• The Amyloid Hypothesis proposes that the buildup of Aβ peptides, especially Aβ42,
leads to the formation of toxic amyloid plaques, causing neuron damage and brain
degeneration. While some Aβ deposits occur with normal aging, excessive
accumulation is linked to AD progression, particularly in inherited cases.

2.4.2 Risk Factors for Alzheimer's Disease (AD):-

1. Aging: The biggest risk factor, as AD mostly occurs after age 65, leading to brain
shrinkage, synapse loss, and memory decline.

2. Genetics: About 70% of AD cases are linked to genes like APP, PSEN1, PSEN2, and
ApoE, which influence Aβ production and accumulation.

3. APP Mutations: Changes in the APP gene on chromosome 21 affect Aβ production,

leading to toxic buildup and neurodegeneration.

4. Presenilin Genes (PSEN1 & PSEN2): Mutations in PSEN1 (common) and PSEN2
(rare) alter γ-secretase activity, increasing toxic Aβ42 levels.

5. Apolipoprotein E (ApoE): ApoEε4 raises AD risk, while ApoEε2 may be protective by

influencing Aβ clearance.

6. ECSIT Gene: Involved in mitochondrial function and oxidative stress, contributing to

AD progression.
7. Estrogen Receptor Gene (ESR): Estrogen loss in women increases AD risk, with ERα
and ERβ variations affecting brain function and protection.

2.4.3 Environmental and Medical Risk Factors for Alzheimer’s Disease (AD):-

1. Air Pollution – Pollutants like ozone, nitrogen oxides, and particulate matter can cause
brain inflammation, oxidative stress, and Aβ plaque buildup, increasing AD risk.
2. Diet – A diet rich in antioxidants and vitamins lowers AD risk, while processed foods
and high-calorie intake contribute to oxidative stress and brain damage.
3. Metals – Toxic metals like aluminum, lead, and cadmium can accumulate in the brain,
causing protein misfolding, Aβ aggregation, and neurodegeneration.
4. Infections – Chronic infections (e.g., HSV-1, Chlamydia pneumoniae) can trigger
brain inflammation, accelerate Aβ deposition, and increase AD risk.

Sunrise College of Pharmacy, Udaipur Page 14

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

5. Cardiovascular Diseases (CVDs) – Stroke, heart failure, and hypertension reduce brain
blood flow, promoting neural damage and cognitive decline in AD.
6. Obesity and Diabetes – Excess fat and high blood sugar levels lead to inflammation,
insulin resistance, and Aβ accumulation, increasing AD risk.14

2.4.4 Figure:- shows the risk factors of Alzheimer's disease

2.5 Diagnosis: -

Diagnosis typically involves:

• Cognitive tests to assess memory and thinking skills

• Medical tests to rule out other conditions

• Brain scans to detect changes like atrophy or amyloid plaques

• Lab tests of spinal fluid to measure protein levels

2.6 Treatment: -

Currently, there is no cure for Alzheimer’s disease, but medications can help manage
symptoms:

Sunrise College of Pharmacy, Udaipur Page 15

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

1. Cholinergics – Loss of cholinergic neurons in the brain is linked to cognitive decline.

Drugs: Donepezil, Rivastigmine, Galantamine.

2. Neurotrophins – Growth factors like NGF support nerve survival and may improve
cognition.

3. Antioxidants – Oxidative stress contributes to AD. Antioxidants may slow disease

progression. Drugs: Selegiline, α-Tocopherol (Vitamin E).

4. Statins – Lower Aβ levels and may reduce AD risk. Drugs: Simvastatin, Atorvastatin.

5. NSAIDs – Reduce inflammation and lower Aβ1–42 production. Drugs: Ibuprofen,

Naproxen.

6. Hormone Replacement Therapy (HRT) – Estrogen may protect neurons and delay
AD onset.

7. Excitotoxicity Blockers – Excess glutamate damages neurons. Drugs: Memantine

(blocks NMDA receptors).

8. Diet – A Mediterranean diet (rich in fish, low in saturated fat and red meat) lowers AD
risk.

9. Amyloid Cascade Hypothesis – Aβ protein accumulation is central to AD

development.

10. Diffuse Lewy Body Disease (DLBD) – The second most common dementia, caused
by α-synuclein aggregates, leading to hallucinations and cognitive fluctuations.15

2.5 Prognosis: -

The average life expectancy following diagnosis is 3 to 12 years. The disease is ranked as the
seventh leading cause of death worldwide.

2.6 Prevention and Management: -

• Healthy Diet – A Mediterranean or DASH diet rich in fruits, vegetables, whole grains,
and healthy fats supports brain health.
• Regular Exercise – Physical activity, including aerobic and strength training,
improves cognitive function and reduces dementia risk.
• Mental and Social Engagement – Cognitive training, social interactions, and lifelong
learning help maintain brain resilience.

Sunrise College of Pharmacy, Udaipur Page 16

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Managing Health Conditions – Controlling hypertension, diabetes, obesity, and

depression reduces dementia risk.
• Avoiding Harmful Substances – Reducing smoking, excessive alcohol consumption,
and air pollution exposure protects brain health.16

2.7 Graph showing current cases and future aspects of cases in Alzheimer's in different
countries: -

2.7.1 Figure shows the graph illustrating worldwide projections of Alzheimer's

disease prevalence from 2005 to 2050, showing a continuous rise in cases. The
total number of individuals with Alzheimer's is expected to increase from 25.73
million in 2005 to 106.23 million by 2050. It also differentiates between early-
stage and late-stage cases, indicating a growing demand for intensive care. The
sharp increase highlights the urgent need for improved prevention, treatment, and
healthcare strategies.17

Sunrise College of Pharmacy, Udaipur Page 17

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

2.7.1 Figure shows the global burden of Alzheimer's disease and dementia is
projected to escalate significantly, with costs expected to exceed $1 trillion
annually by 2050. This increase is driven by the growing aging population and
the lack of effective treatments, placing a substantial economic strain on
healthcare systems worldwide.18

Sunrise College of Pharmacy, Udaipur Page 18

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER -3
PARKINSON'S DISEASE

CHAPTER -3

Sunrise College of Pharmacy, Udaipur Page 19

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

PARKINSON'S DISEASE:-
Parkinson’s disease is a movement disorder characterized by tremors, muscle stiffness
(rigidity), slowness of movement (bradykinesia), reduced movement (hypokinesia), loss of
movement (akinesia), and postural instability. It occurs due to the degeneration of dopamine-
producing neurons in the substantia nigra of the brain, leading to a shortage of dopamine, a
chemical responsible for smooth and coordinated movements. A key pathological feature of
Parkinson’s is the presence of Lewy bodies, abnormal protein clumps found in affected brain
cells.

The disease affects about 1 in 1,000 people, with symptoms typically appearing after the age
of 50, though younger individuals can also be affected. The prevalence increases with age, with
significantly higher cases in older populations. It is more common in Western countries than in
China and Africa. In the United Kingdom, an estimated 60,000 to 80,000 people have
Parkinson’s disease, with 22,000 being severely disabled by it.

Early symptoms can be subtle and often include tremors (in about 70% of cases), muscle pain
or stiffness, fatigue, and difficulty performing small tasks like writing or buttoning a shirt. Some
individuals may also experience depression, weight loss, or general slowness. Because these
symptoms can be vague, Parkinson’s is sometimes misdiagnosed as depression, rheumatism,
or even a mild stroke. Diagnosis is primarily based on clinical symptoms and physical
examination, as there is no definitive test for Parkinson’s. Once the characteristic signs become
evident, the disease can be identified, and management strategies can be implemented.19

Parkinson's disease is a movement disorder of the nervous system that worsens over time. The
nervous system is a network of nerve cells that controls many parts of the body, including
movement.

Symptoms start slowly. The first symptom may be a barely noticeable tremor in just one hand
or sometimes a foot or the jaw. Tremor is common in Parkinson's disease. But the disorder also
may cause stiffness, slowing of movement, and trouble with balance that raises the risk of falls.

In the initial stages of Parkinson's disease, your face may show little or no expression. Your
arms may not swing when you walk. Your speech may become soft or slurred. Symptoms get
worse over time.

Sunrise College of Pharmacy, Udaipur Page 20

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Although Parkinson's disease cannot be cured, medicines may help symptoms get better.
Sometimes a healthcare professional may suggest surgery to help control parts of the brain.
This surgery may help lessen symptoms.

3.1 Stages of Parkinson's Disease:-

Neurologists typically break this down into five stages:
• Stage 1:- is the mildest form where symptoms only affect one side of the body. With
the exception of prominent tremors, most patients don’t even notice the changes that
are occurring during this stage. Patients in this stage are often not bothered by their
symptoms and don’t require medications. At this stage I will often recommend exercise
or “pre-hab” with our physical and occupational therapists to promote physical exercise.
• Stage 2:- is also fairly mild but now involves both sides of the body. Patients may start
to be bothered by symptoms but are not impaired or unable to do their normal tasks.
Patients at this stage generally respond well to medications and sometimes can get close
to normal with the right treatments. During stages 1 and 2, medications can make people
feel like they don’t have a degenerative disease at all.
• Stage 3:- is where symptoms start to become more severe, particularly when it comes
to gait and balance. They may require more rehabilitation or start to use assistive
devices to avoid falls. They may need some help with fine motor tasks like buttoning
buttons. Medications may become less effective. This may be the stage at which
advanced therapies, such as deep brain stimulation, may be considered.
• Stage 4:- is where most patients would need some sort of assistive device such as a
walker to get around. Patients are likely to need a caregiver for tasks such as bathing,
cooking and driving. Medications are still helpful, but may need to be decreased due to
side effects or spread out in small doses throughout the day.
• Stage 5:- is where the patient is no longer able to ambulate and would require a
wheelchair to get around. The patient is reliant on a caregiver for most care tasks.20

3.2 Symptoms 20-21: -

Parkinson's disease symptoms can be different for everyone. Early symptoms may be mild, and
you may not even notice them. Symptoms often begin on one side of the body, then affect both
sides. Symptoms are usually worse on one side than the other. Some Parkinson's disease
symptoms are similar to those of other disorders.

Parkinson's symptoms may include:

• Tremors: Rest tremors in the hands or other body parts, typically on one side of the
body.
• Difficulty Walking: A slow, shuffling gait with irregular pacing or stride length.
• Cramped Handwriting: Micrographia, where handwriting becomes unusually small
or cramped.
• Loss of Smell: Known as hyposmia, this can occur years before motor symptoms.

Sunrise College of Pharmacy, Udaipur Page 21

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Sleep Problems: Includes insomnia, excessive daytime fatigue, and sleep-related

disorders.
• Poor Balance: Difficulty regaining balance, indicating damage to basal ganglia, which
control balance.
• Bradykinesia: Slowness of movement, including stiffness and difficulty initiating
movements.
• Facial Masking: Reduced facial expressions, appearing emotionless despite normal
emotional capacity.
• Vocal Changes: Softer voice or monotonous speech with less variation in tone.
• Hunched Posture: Stooping or bending forward due to muscle rigidity.
• Constipation: A common non-motor symptom, experienced by many before motor
symptoms.
• Psychological Symptoms: Changes in mood, including depression, anxiety, confusion,
and cognitive difficulties.
• Weight Loss: Unexplained weight loss due to factors like tremors or reduced appetite.21

3.2.1 Figure shows the comparison of the actual and hidden symptoms of Parkinson’s
disease.

Sunrise College of Pharmacy, Udaipur Page 22

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3.2.2 Figure showing symptoms of Parkinson's disease in the individual. 20

3.2 Causes: -
In Parkinson's disease, nerve cells in the brain called neurons slowly break down or die. Many
Parkinson's disease symptoms are caused by a loss of neurons that produce a chemical
messenger in the brain. This messenger is called dopamine.

Decreased dopamine leads to irregular brain activity. This causes movement problems and other
symptoms of Parkinson's disease. People with Parkinson's disease also lose a chemical
messenger called norepinephrine that controls many body functions, such as blood pressure.

The cause of Parkinson's disease is unknown, but several factors seem to play a role, including:

Sunrise College of Pharmacy, Udaipur Page 23

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Environmental factors. Exposure to certain toxins or other environmental factors may

increase the risk of later Parkinson's disease. One example is MPTP, a substance that
can be found in illegal drugs and is sometimes sold illegally as "synthetic heroin." Other
examples include pesticides and well water used for drinking. But no environmental
factor has proved to be a cause.

• Genes. Specific genetic changes are linked to Parkinson's disease. But these are rare
unless many family members have had Parkinson's disease.

Many changes happen in the brains of people with Parkinson's disease. Researchers are
studying why the changes happen and the roles they play. These changes include:

• The presence of Lewy bodies. Clumps of proteins in the brain are associated with
Parkinson's disease. These are called Lewy bodies, and researchers believe these
proteins hold an important clue to the cause of Parkinson's disease.

• Alpha-synuclein found within Lewy bodies. Alpha-synuclein is a protein found in all

Lewy bodies. It occurs in a clumped form that cells can't break down. This is currently
an important focus among Parkinson's disease researchers. Alpha-synuclein has been
found in the spinal fluid of people who later have Parkinson's disease.

• Altered mitochondria. Mitochondria are powerhouse compartments inside cells that

create most of the body's energy. Changes to mitochondria can cause cell damage.
These changes have been found in the brains of people with Parkinson's disease. 22

3.3 Risk factors: -

Risk factors for Parkinson's disease include:

• Age:- The risk of Parkinson's disease increases with age. Usually, it starts around age
50 or older. The average age of onset is around age 70. Parkinson's disease can occur in
younger adults, but it is rare. When people younger than age 50 have the disease, it's
known as early-onset Parkinson's disease.

• Genetics:- Having one or more first-degree relatives, such as parents or siblings, with
Parkinson's disease increases your risk. Your risks are still small unless you have many
blood relatives with the condition.

• Male sex:-Men are more likely to develop Parkinson's disease than are women.

Sunrise College of Pharmacy, Udaipur Page 24

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Exposure to toxins:- Ongoing exposure to herbicides and pesticides may slightly

increase your risk of Parkinson's disease.

3.4 Prevention: -

Because the cause of Parkinson's disease is not known, there are no proven ways to prevent it.
Research shows that some factors may help protect against it. But scientists don't know for
sure. These factors include:

3.4.1 Diet and Parkinson’s Prevention: -

Research suggests that diet and exercise may help delay or prevent Parkinson’s disease (PD).

Mediterranean Diet

This diet includes fruits, vegetables, whole grains, olive oil, and fish while limiting dairy and
red meat. Studies suggest it lowers PD risk and delays symptoms by reducing inflammation
and oxidative stress.
Key Guidelines: -

• Eat mostly plant-based foods (fruits, vegetables, nuts, legumes, and whole grains).
• Choose lean proteins like chicken and fatty fish (salmon, tuna, mackerel).
• Limit red meat and dairy products.
• Use olive oil instead of butter.
• Flavor food with herbs and spices instead of salt.
• Drink red wine in moderation.
MIND Diet: -

A mix of the Mediterranean and DASH diets, the MIND diet is also linked to lower PD risk. It
emphasizes leafy greens and berries, which contain flavonoids that slow cognitive decline.
Key Guidelines: -

• Focus on vegetables, whole grains, nuts, beans, and olive oil.

• Eat berries and leafy greens regularly.
• Avoid butter, fried foods, red meat, and sweets

3.4.2 Exercise and Parkinson’s Disease Prevention

Regular exercise may lower the risk of Parkinson’s disease by reducing inflammation,
oxidative stress, and toxic protein buildup in the brain. It also helps maintain a healthy
weight and boosts vitamin D levels if done outdoors.
• Types of Exercise:
Moderate: Walking, cycling, gardening, household chores.

Sunrise College of Pharmacy, Udaipur Page 25

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Vigorous: Jogging, swimming, hiking, tennis.

• Guidelines:
150 minutes of moderate or 75 minutes of vigorous activity per week (CDC & AHA
recommendations).
Choose activities you enjoy and start gradually.
Consult a doctor before starting a new routine.
• Other Benefits:
Exercise improves mood, energy, muscle strength, and overall health. For those with
Parkinson’s, activities like dancing, yoga, and tai chi can help manage symptoms.

3.4.3 Caffeine: - Some studies show a link between drinking caffeinated beverages such as
coffee and green tea and a lower risk of Parkinson's disease.

3.4.4 Medicines: - Some medicines, such as ibuprofen and statins, have been linked to a
lower risk of the disease 24

3.5 Diagnosis: -

Currently, there isn't a specific test to diagnose Parkinson's disease. A diagnosis is made by a
doctor trained in nervous system conditions, known as a neurologist. A diagnosis of Parkinson's
is based on your medical history, a review of your symptoms, and a neurological and physical
exam.

It can take time to diagnose Parkinson's disease. Healthcare professionals may recommend
regular follow-up appointments with neurologists trained in movement disorders to evaluate
your condition and symptoms over time and diagnose Parkinson's disease.

Your healthcare team may order some of these tests and procedures:

• Physical and neurological exam. This includes taking your medical history and doing
a neurological exam that tests your thinking and mental abilities, senses, coordination,
and reflexes.

• Blood and lab tests. These are used to rule out other conditions that may be causing
your symptoms.

• Imaging tests, such as an MRI, brain ultrasound and PET scan. These are used to
rule out other conditions. They are not very helpful in diagnosing Parkinson's disease.

• A specific single-photon emission computerized tomography (SPECT) scan called

a dopamine transporter (DAT) scan. This can help support the suspicion that you
have Parkinson's disease and help identify different types of tremors. But it is your

Sunrise College of Pharmacy, Udaipur Page 26

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

symptoms and the results of your neurological exam that determine your diagnosis.
Most people do not require a DAT scan.

3.5.1 Figure:- Molecular imaging of dopaminergic dysfunction in Parkinson’s

disease. PET and SPECT imaging in a PD patient show reduction
of VMAT2 activity, DAT availability, and DDC activity compared with a healthy
control. DAT = dopamine transporter; DDC = dopa decarboxylase; PD = Parkinson’s
disease; VMAT2 = type 2 vesicular monoamine transporter. Reproduced with permission from
Politis M (2014). PET = positron emission tomography; SPECT = single-photon emission
computed tomography;

3.5.2 Figure:- Molecular imaging of glucose metabolism and PDE10A expression in

Parkinson’s disease. PET imaging shows decreased glucose metabolism
and PDE10A expression in a patient with PD compared with a healthy control. PD =
Parkinson’s disease; PDE10A = phosphodiesterase 10 A; PET = positron emission tomography.
Reproduced with permission from Politis M (2014)

• Genetic testing. This tests for gene changes if there is a known family history of
Parkinson's disease or if you have early-onset disease.

A short, low-dose treatment of medicines. You may be given medicines used to treat
Parkinson's disease to see if you get better. If your symptoms show significant improvement,

Sunrise College of Pharmacy, Udaipur Page 27

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

this may help confirm your diagnosis. You must be given a sufficient dose to show the benefit,
as getting low doses for a day or two isn't reliable.

• Follow-up appointments. Regular appointments with neurologists trained in

movement disorders may be needed over time to confirm a diagnosis. 25-26

• Alpha-synuclein test. This test, also called an alpha-synuclein seed amplification

assay, detects Parkinson's disease before symptoms begin. Alpha-synuclein clumps are
a hallmark sign of Parkinson's disease. Healthcare professionals can test for this
condition in the skin or spinal fluid.

Alpha-synuclein is found in Lewy bodies. It forms clumps that the body can't break down. The
clumps spread and damage brain cells.

In a 2023 study, researchers tested the spinal fluid of more than 1,000 people to look for clumps
of the protein alpha-synuclein. The test accurately identified people with Parkinson's disease
87.7% of the time. The test also was extremely sensitive for detecting people at risk of
Parkinson's disease.

This study of the alpha-synuclein seed amplification assay was the largest so far. Some
researchers say the study may be a breakthrough for Parkinson's disease diagnosis, research,
and treatment trials. But larger studies are needed.

There's hope among researchers that in the future, the test could be done using blood samples
rather than spinal fluid.27

3.6 Medicines: - 28-30

Medicines may help improve problems with walking, movement, and tremor. The medicines
work by increasing or substituting for dopamine in the brain.

People with Parkinson's disease have low levels of brain dopamine. But dopamine cannot be
given directly because it cannot enter the brain.

Your symptoms may improve significantly after you start treatment. The benefits may lessen
over time, but usually medicines still control symptoms well.

Medicines you may be prescribed include:

3.6.1 Levodopa: - Levodopa is the main treatment for Parkinson's disease (PD) because it
replaces dopamine in the brain. It crosses the blood-brain barrier and is converted into
dopamine to help with motor symptoms.

Sunrise College of Pharmacy, Udaipur Page 28

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

1. Action: Levodopa is converted to dopamine in the brain to treat PD.

2. Dosage: It’s started at a low dose and gradually increased, typically in divided doses
(150–1000 mg/day). The effect may wear off faster as the disease progresses.

3. Side Effects: Includes nausea, vomiting, orthostatic hypotension, dyskinesias

(involuntary movements), and motor fluctuations ("on-off" phenomenon).

4. Management:

o Combined with drugs like carbidopa or benserazide to reduce peripheral side

effects.

o Modified release formulations help control symptoms for longer.

5. Advanced Treatment: Continuous intestinal infusion of levodopa gel is effective but

expensive.

Levodopa is effective but needs careful management to minimize side effects, especially in the
advanced stages of PD.

3.6.2 Dopamine Agonists: -

Dopamine agonists, introduced in 1978, are used to treat Parkinson’s disease (PD) by
stimulating dopamine receptors directly, unlike levodopa. They are often prescribed to younger
PD patients to delay the use of levodopa and reduce motor complications.

Types: They are classified into ergot (e.g., pergolide) and non-ergot types (e.g., ropinirole,
pramipexole). Some, like pergolide, were withdrawn due to severe side effects.

Formulations: Dopamine agonists come in tablets, patches, and injections. Rotigotine patches
are useful for patients who can’t take oral medications, such as those who are nil-by-mouth
before surgery.

Dosage: The dosage is adjusted based on patient response. Common doses are:

• Ropinirole: 9–16 mg daily in 3-4 doses.

• Pramipexole: 3.3 mg daily in 3 doses.

• Rotigotine: 4–6 mg once daily.

• Apomorphine: Used for severe motor fluctuations, injected subcutaneously.

Benefits: They help reduce motor fluctuations and dyskinesia compared to levodopa but are
less effective overall.

Side Effects: Common ones include nausea, dry mouth, and insomnia. A major risk is impulse
control disorders (ICD), such as gambling or hypersexuality, seen in 15–20% of users.

Sunrise College of Pharmacy, Udaipur Page 29

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Withdrawal Syndrome: Abrupt stopping or reducing the dose can cause anxiety, insomnia,
and cravings, so withdrawal needs to be managed carefully

3.6.3 Monoamine Oxidase B (MAO-B) Inhibitors: - These are the medications used in
Parkinson’s disease (PD) to increase dopamine levels by inhibiting the enzyme MAO-B, which
breaks down dopamine. This helps preserve dopamine activity in the brain, particularly in the
striatum, and relieves motor symptoms.

Uses:

• MAO-B inhibitors are often used early in PD to delay the need for levodopa and reduce
levodopa-related motor complications.

• They can be used alone in early disease or combined with levodopa to reduce the
levodopa dose.

Common MAO-B Inhibitors:

• Selegiline (Deprenyl, Eldepryl, Zelapar)

• Rasagiline (Azilect)

• Safinamide (Xadago), which has multiple actions, including MAO-B inhibition.

Dosage:

• Selegiline: 5–10 mg daily.

• Rasagiline: 0.5–1 mg once daily.

Side Effects:

• Gastrointestinal issues (most common).

• Other effects: aching joints, depression, fatigue, dry mouth, insomnia, dizziness,
confusion, hallucinations, and headaches.

3.6.4 Catechol-O-methyl transferase (COMT) inhibitors: - help increase dopamine

levels by blocking the enzyme COMT, which breaks down dopamine. These are used
alongside levodopa to extend its effect, particularly in patients who experience "wearing-
off" between doses of levodopa.

Key Points: -

1. Action: - COMT inhibitors prolong levodopa's effect by preventing dopamine

breakdown.

2. Use: - Typically prescribed with levodopa, not alone, as they have limited effect on PD
symptoms.

Sunrise College of Pharmacy, Udaipur Page 30

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3. Examples: -

o Entacapone (Comtan)

o Tolcapone (Tasmar)

o Opicapone (Ongentys)

4. Dosage: - Entacapone is usually taken 200 mg four to eight times daily with levodopa,
and tolcapone is taken 100 mg three times daily.

5. Side Effects: - Can amplify levodopa's side effects (e.g., dyskinesias) and may require
reducing levodopa dose. Tolcapone can cause liver damage, so liver function is
monitored. Other side effects include nausea, dizziness, confusion, and orange urine.

COMT inhibitors are effective in extending levodopa’s action but come with potential side
effects, especially when combined with levodopa.

3.6.5 Anticholinergics: - These are the drugs that reduce the activity of acetylcholine,
helping to restore the balance between dopamine and acetylcholine in the brain. They are
less commonly used today but can help with tremors and muscle stiffness in Parkinson’s
disease (PD), particularly in younger patients with mild symptoms.

Key Points: -

1. Action: - These drugs block cholinergic receptors, reducing acetylcholine activity.

2. Use: - Mostly for younger patients in the early stages of PD to alleviate tremors and
rigidity. They are sometimes used with levodopa in combination therapy.

3. Examples: -

o Benztropine

o Orphenadrine

o Procyclidine

o Trihexyphenidyl (Benzhexol)

4. Side Effects: - Common side effects include blurred vision, dry mouth, constipation,
drowsiness, confusion, memory problems, hallucinations, and urinary retention.
However, reduced salivation can be beneficial for treating drooling in some patients.

5. Precautions: - Generally avoided in elderly patients or those with cognitive issues due
to the risk of confusion and cognitive impairment.

Anticholinergics can help control specific symptoms like tremors but are not commonly
used due to their side effects, particularly in older individuals.

Sunrise College of Pharmacy, Udaipur Page 31

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3.6.6 Amantadine: - Amantadine (Symmetrel) was originally developed as an antiviral

drug but is now used to treat Parkinson's disease (PD). It can help with rigidity, rest tremors,
and fatigue, and may reduce levodopa dosage, lowering the risk of dyskinesias. It is
particularly useful for controlling levodopa-induced dyskinesias. However, evidence for its
effectiveness in PD is limited.

Key Points:

1. Action: Amantadine is a weak glutamate antagonist that may help reduce Parkinson’s
symptoms, especially dyskinesias.

2. Use: It is used to treat rigidity, tremors, and fatigue, and can allow for lower levodopa
doses.

3. Dosage: It is started at a low dose and increased gradually. Available in tablets and
liquid form.

4. Side Effects: Common side effects include hallucinations, confusion, leg swelling,
blurred vision, nausea, insomnia, and agitation. A specific skin condition, livedo
reticularis, may also occur.

Amantadine may be helpful in managing PD symptoms, especially dyskinesias, but it is not

universally recommended due to limited evidence supporting its broader use.

3.7 Other therapies: -

Other therapies that may help manage Parkinson’s symptoms include:

• Physical, occupational, and speech therapies, which may help with gait and voice
disorders, tremors and rigidity, and decline in mental functions

• A healthy diet to support overall wellness

• Exercises to strengthen muscles and improve balance, flexibility, and coordination

• Massage therapy to reduce tension

Sunrise College of Pharmacy, Udaipur Page 32

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3.7.1 Figure: - shows the combinations of drugs to treat Parkinsons disease it involves a class
of drugs, examples of the category, therapeutic indications, motor benefits, and common
adverse effects.

Sunrise College of Pharmacy, Udaipur Page 33

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3.7.2 Figure: - The graph shows the number of deaths caused by Parkinson’s
disease and multiple sclerosis in England over time, from 1860 to 2010.
Parkinson’s deaths have risen sharply, especially after 1980, while multiple
sclerosis deaths have remained relatively stable with a slight increase.31

Sunrise College of Pharmacy, Udaipur Page 34

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

3.7.3 Figure: -The image is a bar chart showing the global projected increase in
Parkinson’s disease cases over time. It indicates that the number of cases rose
from 2.6 million in 1990 to 6.3 million in 2015 and is expected to reach 12.9
million by 2040, highlighting the growing burden of the disease.32

Sunrise College of Pharmacy, Udaipur Page 35

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER -4
AMYOTROPHIC LATERAL
SCLEROSIS

Sunrise College of Pharmacy, Udaipur Page 36

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER 4

AMYOTROPHIC LATERAL SCLEROSIS

4.1 Introduction: - Amyotrophic lateral sclerosis (ALS) is a fatal disease that affects motor
neurons, leading to muscle weakness, paralysis, and respiratory failure. It is also called
Charcot’s disease in France and Lou Gehrig’s disease in the U.S. In Europe, it is often known
as Motor Neuron Disease (MND).

ALS damages the motor cortex, brainstem, and spinal cord neurons, causing loss of voluntary
muscle control. The term amyotrophic refers to muscle wasting, lateral to the spinal cord
pathways involved, and sclerosis to tissue hardening.

The disease affects 0.3 to 2.4 people per 100,000 globally, with 95% of cases being random
(sporadic ALS) and about 5% inherited (familial ALS). Despite being studied for over 150
years, there is no cure, but research is progressing in genetics, diagnostics, and treatments.
Scientists are focusing on genetic mutations like Cu-Zn-superoxide dismutase (Cu ZnSOD),
FUS/TLS, and TDP43 to develop new .33

Amyotrophic lateral sclerosis (ALS) is a degenerative disease that affects the brain and spinal
cord. It causes a worsening loss of voluntary muscle control affecting movements like talking,
swallowing, and walking.

There is currently no cure for ALS. However, treatments are available that can reduce
symptoms and may help people with ALS to live longer.

The famous baseball player Lou Gehrig developed symptoms of the condition in the 1930s, and
that’s why it’s also known as Lou Gehrig’s disease.

Every year, about 5,000 people in the United States receive an ALS diagnosis. Around 30,000
people in the U.S. are currently living with the condition. ALS affects people in all racial, social,
and economic groups.

A 2016 study Trusted Source suggests that ALS is becoming more common. This may be
because the population is aging.34

Sunrise College of Pharmacy, Udaipur Page 37

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

4.2 Symptoms

The early signs of ALS appear when muscles start to weaken, and they can vary from person
to person. Initially, the symptoms may be so mild that they go unnoticed, affecting one or
multiple areas of the body.

For many, the first signs appear in the arms and legs (limb onset ALS), while about one-third
of cases begin with speech or swallowing difficulties (bulbar onset ALS).

Common Early Signs of ALS:

• Weakness in arms and hands: One hand or arm may become weak first, followed by
the other over time. Tasks like buttoning a shirt or unlocking a door become difficult,
and dropping objects may occur more often.

• Leg weakness: One leg may weaken first, leading to tripping, stumbling, and falls. The
other leg also weakens over time, making walking challenging.

• Muscle stiffness (spasticity): Increased muscle tone causes tightness, interfering with
normal movement.

• Muscle twitches and cramps (fasciculations): Twitches often occur during sleep,
usually in the hands, feet, or tongue.

• Slurred speech (dysarthria): Speech may sound "thick" or nasal due to weakening
facial muscles, making it harder to project the voice.

• Difficulty swallowing (dysphagia): Caused by weakened facial and tongue muscles.

• Breathing difficulties (dyspnea): Shortness of breath, though less common as an early

symptom.

• Fatigue: General tiredness and weakness in the limbs.

• Uncontrolled laughing or crying (pseudobulbar affect): Emotional expressions that

are not tied to actual emotions, likely due to brain circuit disruptions, with crying being
more common than laughing.35

4.3 Causes: -

ALS affects the nerve cells that control voluntary muscle movements such as walking and
talking. These nerve cells are called motor neurons. There are two groups of motor neurons.

Sunrise College of Pharmacy, Udaipur Page 38

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

The first group extends from the brain to the spinal cord to muscles throughout the body.
They're referred to as upper motor neurons. The second group extends from the spinal cord to
muscles throughout the body. They're referred to as lower motor neurons.

ALS causes both groups of motor neurons to gradually deteriorate and then die. When motor
neurons are damaged, they stop sending messages to the muscles. As a result, the muscles can't
function.

For about 10% of people with ALS, a genetic cause can be identified. For the rest, the cause is
not known.

Researchers continue to study possible causes of ALS. Most theories center on a complex
interaction between genes and factors in the environment.
ALS (Amyotrophic Lateral Sclerosis) is believed to result from a combination of genetic,
environmental, and age-related factors. Over 20 genes have been linked to ALS, with more
expected to be discovered. The genetic aspect of ALS is complex, with monogenic mutations
accounting for about 15% of cases, while other genetic variants also contribute to disease risk.
The overall heritability of ALS is estimated to be between 30% and 60%, and having a first-
degree relative with ALS doubles the risk of developing the disease.
Key Genetic Causes of ALS: -

Figure: - The image shows three types of genetic mutations: substitution (replacement of one
nucleotide), insertion (addition of extra nucleotides), and deletion (removal of a nucleotide).
These mutations can alter the genetic code, potentially affecting protein function and leading
to diseases.36
• SOD1 (1993): Accounts for 20% of familial ALS (fALS) and 1%–2% of sporadic ALS
(sALS). Mutations cause protein aggregation, disrupting cellular functions.
• TARDBP & FUS (2008–2009): Encode RNA-binding proteins TDP-43 and FUS,
responsible for 3%–5% of fALS and <1% of sALS.

Sunrise College of Pharmacy, Udaipur Page 39

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• C9orf72 (2011): The most common genetic cause, linked to 30%–50% of fALS and
7%–10% of sALS. Associated with cognitive and behavioral impairments.
• TBK1: The fifth most common gene mutation, responsible for about 1% of ALS cases
but up to 10% in ALS-FTD (ALS with frontotemporal dementia).
While SOD1 mutations have high penetrance, other ALS-related genes show reduced
penetrance, making genetic counseling more challenging. Some patients may carry mutations
in multiple genes, suggesting an oligogenic cause. Advances in next-generation sequencing
have identified additional rare variants, many of which are linked to specific disease
pathways.37

Figure:- Image showing the causes and risk factors of ALS 38

4.4 Risk Factors and ALS: -
4.4.1 Smoking:-

Sunrise College of Pharmacy, Udaipur Page 40

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Cigarette smoking is one of the strongest non-genetic risk factors for ALS.

• Smoking increases ALS risk through oxidative stress, inflammation, and heavy metal
toxicity.

• Starting smoking at a young age raises the risk, but duration and intensity of smoking
do not matter.

• Formaldehyde in cigarettes is linked to higher ALS mortality.

• The effects of quitting smoking on ALS risk remain unknown.

4.4.2 Physical Activity: -

• Athletes have a higher risk of ALS, but no direct link exists between general physical
activity and ALS.

• Some genes related to exercise and vascular health may also contribute to ALS
susceptibility.

• A genetic profile promoting physical fitness might explain the higher ALS risk in
athletes.

• Studies show ALS patients and their relatives have fewer heart diseases, supporting a
possible genetic connection.

4.4.3 Chemical and Metal Exposure: -

• Pesticides, herbicides, and formaldehyde are linked to ALS.

• Four or more years of exposure to pesticides/herbicides may increase ALS risk.

• Formaldehyde exposure (common in cigarettes and industrial settings) doubles the ALS
mortality rate.

• Lead exposure has been studied the most due to its ALS-like symptoms.

• Jobs involving lead exposure (e.g., welding) show a higher risk of ALS (odds ratio 1.9–
5.7).

• Lead may contribute to ALS by damaging mitochondria and increasing neuron toxicity.

• However, some studies found no strong link between ALS and lead when using expert
evaluations instead of self-reported data, suggesting recall bias may be an issue.

4.4.4 Electromagnetic Fields and Radiation :-

Sunrise College of Pharmacy, Udaipur Page 41

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Low-frequency electromagnetic waves generate oxidative stress, a key factor in ALS.

• In laboratory studies, exposure caused DNA damage and neuron death.

• Some studies link electromagnetic fields to ALS risk, but no conclusive evidence exists.

4.4.5 Diet and ALS Risk: -

• Harmful Foods:

o High levels of glutamate and fat may worsen ALS symptoms.

o Glutamate, found in protein-rich foods (e.g., tomatoes, mushrooms, milk,

cheese), may contribute to neuronal death in ALS.

• Protective Nutrients:

o Omega-3 fatty acids and Vitamin E have anti-inflammatory effects and may
reduce ALS risk by up to 60%.

Fiber may also have a protective effect39

4.3 Diagnosis 40-41: -

Diagnosing ALS is challenging because no single test can confirm it. Instead, healthcare
providers use a combination of tests and examinations to reach a diagnosis:

• Physical examination of ALS typically reveals muscle weakness, atrophy, and

fasciculations (muscle twitches), often starting in one limb or facial muscles.
Hyperreflexia and Babinski signs may also be present, indicating upper motor neuron
involvement.

• Neurological examination: Assesses muscle strength, dexterity, reflexes, and

coordination.

• Electromyography (EMG): Measures electrical activity in muscles.

• Nerve conduction velocity test (NCV): Evaluates the speed of electrical impulses
through nerves.

• Blood tests: Help rule out other conditions with similar symptoms.

• Urine tests: Check for heavy metal exposure, which may be linked to nerve damage,
though not definitively connected to ALS.

Sunrise College of Pharmacy, Udaipur Page 42

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Imaging studies (X-rays, MRI): Rule out ALS and identify other potential causes of
symptoms.

• Muscle biopsy (rarely used): Examines tissue for signs of muscle diseases with ALS-
like symptoms.

4.5 Treatment 42-43: -

Treatments can't reverse the damage of ALS, but they can slow the progression of symptoms.
They also can help prevent complications and make you more comfortable and independent.

You might need a team of health care providers and doctors trained in many areas to provide
your care. The team works together to prolong your survival and improve your quality of life.

Your team works to select the right treatments for you. You have the right to choose or refuse
any of the treatments suggested.

4.5.1 Medications: -

The Food and Drug Administration has approved two medicines for treating ALS:

➢ Riluzole: The first FDA-approved treatment for ALS in 1995. It works by reducing
overstimulation of nerve cells. Available in three formulations:

• Rilutek: Oral tablet by Covis Pharma.

• Tiglutik: Liquid suspension for oral or feeding tube use.

• Exservan: Oral film that dissolves on the tongue.

➢ Edaravone: FDA-approved in 2017 to reduce oxidative stress in ALS. Available in two

formulations:

• Radicava: Intravenous infusion by Mitsubishi Tanabe Pharma.

• Radicava ORS: Oral suspension for mouth or feeding tube use, approved in 2022.

➢ Relyvrio: A combination of sodium phenylbutyrate and taurursodiol, approved in late

2022 but removed from the market in April 2024 due to negative clinical trial results.
Available to patients in a free drug program.
➢ Qalsody: An RNA-based therapy approved in April 2023 for ALS patients with SOD1
mutations. It reduces toxic SOD1 protein buildup through injection therapy by Biogen.

4.5.2 Treating ALS symptoms: -

In addition to treatments targeting the underlying causes of ALS, several therapies help manage
its specific symptoms:

Sunrise College of Pharmacy, Udaipur Page 43

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Muscular symptoms (weakness, wasting, tremors): Physical and occupational therapy

can help maintain mobility and manage muscle function.

• Spasticity and cramps: Medications like baclofen or tizanidine may relieve muscle
stiffness and spasms.

• Difficulty speaking and swallowing: Speech therapy and assistive communication

devices can aid in communication, while swallowing difficulties may be addressed with
dietary modifications or feeding tubes.

• Trouble breathing: Non-invasive ventilation (NIV) or invasive ventilation may be

used to support respiratory function.

• Digestive issues (constipation): Laxatives or dietary adjustments can manage

constipation and other digestive complaints.

• Cognitive and behavioral abnormalities: Cognitive behavioral therapy (CBT) and

medications may help manage cognitive changes or behavioral issues.

• Mental health: Antidepressants or counseling can assist in managing mental health

concerns like depression or anxiety.

4.5.3 Treatments for spasms and cramps: -

Treatment of spasticity and cramps generally involves medicines that prompt muscles to relax.
A number of therapies are approved to treat spasticity including:

• baclofen

• tizanidine

• formulations of botulinum toxin, such as Dysport

• dantrolene.

4.5.4Treatments for excess saliva production: -

Medications used to manage saliva production in ALS are mainly anticholinergic therapies,
which block signals from nerves that promote saliva production in the salivary glands.
Examples of these medicines that are commonly used in ALS include:

• scopolamine

• amitriptyline

• carbocisteine

Sunrise College of Pharmacy, Udaipur Page 44

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• atropine.

4.5.5 Stem Cell Treatment for ALS: -

Stem cells are undifferentiated cells in the body that are capable of self-renewing and maturing
into other types of cells. They also can secrete signaling molecules that provide a supportive and
protective environment to nearby cells.

Scientists have explored many treatment strategies for ALS that utilize stem cells, though so far
none has been approved by the FDA.

Such ALS stem cell treatment is not the same thing as stem cell transplants, which are procedures
used to manage certain cancers and autoimmune diseases. Stem cell transplants work by replacing
the blood stem cells that live in the bone marrow.

4.5.6 Other Therapies: -

When ALS affects your ability to breathe, speak and move, therapies and other forms of support
can help.

• Breathing care. Most people with ALS eventually have more trouble breathing as
muscles weaken. Your health care provider might test your breathing regularly and provide
devices known as mechanical ventilation to assist your breathing at night.

You might choose to use a ventilator with a mask that can easily be applied and removed. This
is known as noninvasive ventilation. Some people eventually have surgery that creates a hole
at the front of the neck leading to their windpipe. This is called a tracheostomy. A tube inserted
into the hole connects to a respirator to help them breathe. Sometimes people with ALS who
have a tracheostomy also have a type of surgery called a laryngectomy. This surgery prevents
food from entering the lungs.

• Physical therapy. A physical therapist can address pain, walking, mobility, bracing and
equipment needs that help you stay independent. Practicing low-impact exercises can help
maintain your cardiovascular fitness, muscle strength and range of motion for as long as
possible.

Regular exercise also can help improve your sense of well-being. Appropriate stretching can
help prevent pain and help your muscles function at their best.

A physical therapist also can help you overcome weakness by using a brace, walker or
wheelchair. The therapist might suggest devices such as ramps that make it easier for you to
get around.

Sunrise College of Pharmacy, Udaipur Page 45

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

• Occupational therapy. An occupational therapist can help you find ways to remain
independent despite hand and arm weakness. Adaptive equipment can help you perform
activities such as dressing, grooming, eating and bathing.

An occupational therapist also can help you modify your home to allow accessibility if you
have trouble walking safely.

• Speech therapy. A speech therapist can teach you adaptive techniques to make your
speech more understandable. Speech therapists also can help you find other ways to
communicate. These may include using a smart phone app, alphabet board, or pen and paper.

Ask your therapist about the possibility of recording your own voice to be used by a text-
tospeech application.

• Nutritional support. Your team typically works with you and your family members to
ensure you are eating foods that are easier to swallow and meet your nutritional needs. You
might choose to have a feeding tube placed when it becomes too hard to swallow.

• Psychological and social support. Your team might include a social worker to help
with financial issues, insurance, and getting equipment and paying for devices you need.
Psychologists, social workers and others may provide emotional support for you and your
family.

Sunrise College of Pharmacy, Udaipur Page 46

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

4.6 Worldwide Graphical Data: -

4.6.1 FIGURE: - Prevalence of amyotrophic lateral sclerosis (ALS), by age group —

National ALS Registry, United States, 2012–2014.44

Sunrise College of Pharmacy, Udaipur Page 47

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

4.6.2 TABLE:- Number and percentage of identified cases of amyotrophic lateral sclerosis (N
= 15,927) and estimated prevalence, by age group, sex, race, and geographic region —
National ALS Registry, United States, 2014.44

Sunrise College of Pharmacy, Udaipur Page 48

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER-5

AYURVEDIC TREATMENT OF
NEURODEGENERATIVE DISEASE

AYURVEDIC TREATMENT OF NEURODEGENERATIVE DISEASE

Sunrise College of Pharmacy, Udaipur Page 49

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

5.1 Introduction: -

Ayurveda means the science of life. The scientific methodology of Ayurveda consists of the
knowledge passed on by the sages, direct observation, inference, and deductive logic as well
as experimentation. The physical body is made of five prime elements. These
are Prithvi (earth), Tejas (fire), Vayu (air), and Akasha (sky). These five elements are present
in different proportions in different structures and functions of the body, as well as the universe
outside. There are triads of constitutional physical and psychological correlates
termed Tridosha and Triguna. Treatment of disorders in Ayurveda is holistic in nature and
consists of medicine, diet, lifestyle changes, and psychological counselling.45

Ayurveda is most world‟s oldest medical system and remains one of the India‟s traditional
health caresystem & incertain cases, it is even supposed to be the most effective than modern
medicine. Ayurvedic treatment carry ayurvedic product which are mainly produced from plant
but may also include animal, metal, minerals and it also combined diet exercise and lifestyle.
Ayurveda is also called as ancient Indian medical system.[2] newly 20,000 medicinal plant
species has been reported and around 500 traditional communities use about 800 plant species
for treatment of version elements. according to the world health organisation(WHO)
investigation report about 70% of Indian population use traditional and alternative medicines
for healing different diseases. There are to distinct types of dosage form in ayurvedic system,
which are Arista(fermented decortion) and Asava (fermented infusion)are considered as highest
to other dosage form due to their easy palatability, accelerated therapeutic actions and increase
the drug concentration.46

Sunrise College of Pharmacy, Udaipur Page 50

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

5.2 Medications: -

Ayurveda is the universe of knowledge and contains lots of medicine but here we discuss some
of the important medicines used in neurodegenerative disease and which play an important role
in it.

5.2.1 Withania somnifera /Ashwagandha: -

Withania somnifera (Family: Solanaceae), commonly known as Ashwagandha or Indian

ginseng is distributed widely in India, Nepal, China, and Yemen. The roots of plants consist of
active phytoconstituents mainly withanolides, alkaloids, and sitoindosides, and are
conventionally used for the treatment of multiple brain disorders.

Ashwagandha belongs to the family Solanaceae. Other common names of Ashwagandha are
Indian ginseng, poison gooseberry and winter cherry. Ashwagandha is cultivated in North
western and central part of India. In India Madhya Pradesh, Gujarat, Haryana, Maharashtra,
Punjab, Rajasthan and Uttar Pradesh are the main producing state of Ashwagandha. It is also
found in Nepal, China and Yemen. The climatic conditions required for the cultivation of
Ashwagandha include an altitude of 1500 m above the sea level. The semi tropical regions
which receive about 500–800 mm annual rainfall are the best suited for its cultivation. The
crops require dry condition during growing periods and optimum temperature required for its
cultivation is 20–38 °C. The sandy loam or light red soil and partial shade sun are other suitable
factors for its growth.

The extract of roots contains steroidal lactones with ergostane, which contain withanone,
withaferin, withanolides, sitoindosides and about 0.2% alkaloids. Various studies have been
conducted on active phytoconstituents which helps in providing a rationale background for
drug design with upgraded and better pharmacological properties. The herb is reported to
possess beneficial effects in a wide range of neurological disorders including stress, Parkinson's
disease, Huntington's disease and Alzheimer's disease etc. Ashwagandha modulates the brain
oxidative stress makers, such as superoxide dismutase (SOD), catalase, lipid peroxidation
(LPO), and non-enzymatic antioxidants like glutathione (GSH). The roots and its extract induce
axon and dendrite outgrowth, proposing its possible effect on neuronal regeneration

Currently, patents are considered as the most significant and reliable source of information.
Patents contain information in all depths and breaths and is estimated that 70–75% of
information are not available anywhere else.

Sunrise College of Pharmacy, Udaipur Page 51

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Various patents on Ashwagandha are available either alone or in combinations with other
medicinal plants for use in various diseases includes antimicrobial, anti-lipidemic, anti-
diabetic, anti-pyretic, anti-inflammatory, anti-aging, anti-HIV, antiarthritic, anti-bacteria,

Ashwagandha and its extract have been used since decades to treat various disorders.
Ashwagandha is largely used as an immunomodulator in recent times and indicated anti-
diabetic, hepatoprotective, anticancer, and anti-inflammatory activity as
well.47

[Link] Image: -The image shows that Withanolide A and Withanone from Ashwagandha help
in clearing β-amyloid plaques, reducing neurofibrillary tangles, and balancing antioxidant
enzymes (SOD, CAT, GPX, NO) to reduce oxidative stress. This leads to reduced superoxide
generation and lipid peroxidation, offering neuroprotection against Alzheimer's disease.47

Sunrise College of Pharmacy, Udaipur Page 52

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

[Link] Image: - The image summarizes the neuroprotective effects of Withania somnifera
(Ashwagandha) on four major neurodegenerative diseases:

1. Amyotrophic Lateral Sclerosis (ALS): Enhances neuromuscular junctions, reduces

astrogliosis and microgliosis, increases heat shock proteins (HSPs), and reduces protein
misfolding (SOD1, TDP-43).

2. Parkinson's Disease: Increases dopaminergic neuron survival, reduces oxidative

damage, increases DOPA and its metabolites, and regulates antioxidant enzymes (GSH,
SOD, CAT, GPx).

3. Alzheimer's Disease: Facilitates β-amyloid clearance, reduces plaque accumulation,

attenuates oxidative stress, and restores synaptic loss.

4. Huntington's Disease: Protects against basal ganglia lesions, regulates mitochondrial

function and biochemical balance, and increases antioxidant machinery.

The central role of Withania somnifera is in enhancing antioxidant defenses and reducing
oxidative stress, contributing to neuroprotection. 48

Sunrise College of Pharmacy, Udaipur Page 53

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

5.2.2 Centella Asiatica / Asiatica pennywort / Brahmi: -

Specific herbal therapies for the treatment of dementia have been described in Ayurveda, the
ancient Indian system of medicine. Centella Asiatica (Mandukaparni in Sanskrit) is listed as a
treatment for dementia in the ancient Indian Ayurvedic Medical text, Caraka Susmita. This
approach has been continued over the centuries to the modern day as the ingestion of powdered
dry leaves of Centella Asiatica mixed with milk is used in some parts of India as a treatment to
improve memory. Preliminary studies on the central nervous system effect of Centella Asiatica
suggest that extracts of this herb are well tolerated and may have pro-cognitive effects in
humans and rodents. Centella Asiatica improves memory retention in rodents and increases
performance and behavior in mentallyretarded children. Additional Uses of Centella asiatica
include the promotion of a deep state of relaxation and mental calmness during meditation
practices and the alleviation of depression and anxiety when combined with other herbs.49

Centella asiatica is also a vine herb that is widely used and cultivated as a medicinal plant in
Asia. C. asiatica contains numerous active constituents, the most significant of which are
pentacyclic triterpenes, including Asiatic acid (AA), asiaticoside, madecassoside, and
madecassic acid. C. asiatica has extensive pharmacological potential. Recent studies report C.
asiatica to have roles in several conditions, such as reducing oxidative stress, antipyretic,
antidepressant, anticonvulsant, anxiolytic, anticancer, anti-infective, antiwrinkle, wound-
healing, anti-inflammatory properties, and neuroprotective. Despite its wide use in various
cases, the benefits of neuropharmacological use of C. asiatica in TBI are still receiving less
attention. The clinical impact of C. asiatica on TBI has been researched through a number of
randomized controlled trials. However, no studies summarize the evidence on the effects of C.
asiatica on TBI and its associated potency. This study will thoroughly analyze all available data
to verify the impact of C. asiatica on TBI and its related potency

Centella asiatica (Gotu Kola) has been traditionally used in Chinese and Ayurvedic medicine
for cognitive enhancement. Scientific studies have demonstrated its neuroprotective effects,
including its ability to counteract stroke-related damage, promote nerve regeneration, and exert
antioxidant properties. Extracts of C. asiatica (CAW) have been shown to improve cognitive
function in both human trials and animal models. In the Tg2576 mouse model of AD, which
exhibits Aβ accumulation and learning deficits, two weeks of CAW treatment reversed
behavioral impairments and enhanced synaptic gene expression.50

Sunrise College of Pharmacy, Udaipur Page 54

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

In vitro studies further support these findings, showing that CAW protects neurons against Aβ-
induced cell death, oxidative stress, and mitochondrial dysfunction. However, its precise effects
on synaptic plasticity remain unexplored. Moreover, while CAW contains multiple bioactive
compounds, the specific molecules responsible for its neuroprotective properties are yet to be
identified. This study aims to investigate CAW’s impact on dendritic morphology in
hippocampal neurons from both wild-type and AD model animals, potentially uncovering its
role in synaptic resilience .51

[Link] Phytochemical Content of C. Asiatica: -

Centella asiatica contains various bioactive compounds, primarily triterpene saponosides like
asiatic acid, madecassic acid, asiaticoside, and madecassoside. Other key compounds include
flavonoids (quercetin, kaempferol), polysaccharides (centellose), polyacetylenes, sterols, and
phenolic acids (rosmarinic acid, chlorogenic acid). Essential oils from C. asiatica contain
monoterpenes and sesquiterpenes, with α-copaene as the major component in Turkish-origin
samples. These compounds contribute to the plant's therapeutic properties.

Centella asiatica has been used in traditional medicine for treating various diseases. Its
medicinal properties come from key compounds like asiatic acid, asiaticoside, and
madecassoside, along with flavonoids and terpenoids. The plant's secondary metabolites,
mainly pentacyclic triterpenoid saponins, are referred to as centelloids.

A GC-MS analysis of Centella asiatica's essential oil found p-cymene (44%) as a major
component along with other volatile compounds. Several bioactive compounds, including
centellin, asiatic acid, and centellicin, were identified from the plant’s aerial parts using 2D
NMR spectroscopy.

Using HPLC analysis, researchers found significant amounts of madecassoside, asiaticoside,

madecassic acid, and asiatic acid in plant extracts. The highest asiaticoside content (6.42%)
was recorded in leaf samples from the Mangoro region.

Additionally, new triterpenes and saponins have been discovered in Centella asiatica using
spectral methods, further confirming its rich bioactive composition. Overall, its main active
compounds are pentacyclic triterpenes such as asiatic acid, madecassic acid, asiaticoside, and
madecassoside.52

Sunrise College of Pharmacy, Udaipur Page 55

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

[Link] Case Study: -

This study investigates the neuroprotective potential of Centella asiatica (CeA) against chronic
stress-induced neurodegeneration in rats. Chronic stress was induced using movement restraint
and forced swimming for 21 consecutive days, leading to neurodegenerative effects. To assess
CeA’s neuroprotective properties, three different dosages (200, 400, and 800 mg/kg/day) were
administered, and a metabolomics approach was used for evaluation.

The results revealed a significant difference between treated and untreated groups, with CeA
effectively reducing the impact of chronic stress. The extract notably increased the levels of
key brain metabolites, including lactate, isoleucine, proline, methionine, valine, leucine, and
glutamine, with the highest enhancement observed at 800 mg/kg dosage. These metabolites
play crucial roles in brain function, contributing to neurotransmitter synthesis, protein
synthesis, energy metabolism, oxidative stress protection, and glutamate
compartmentalization.

Overall, this study highlights CeA’s potential as a natural neuroprotective agent, offering a
promising alternative to conventional therapies for managing neurodegeneration associated
with chronic stress. Further research could help elucidate its precise molecular mechanisms
and therapeutic applications.53

Sunrise College of Pharmacy, Udaipur Page 56

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

[Link] Image: This image illustrates the neuroprotective effects of compounds from Centella
asiatica, such as asiatic acid and madecassoside. These compounds target key cellular
pathways to preserve mitochondrial function, offering antioxidative and mitoprotective
benefits. By restoring mitochondrial health, they help reduce inflammation and neuronal loss,
ultimately promoting neuronal survival.54

Sunrise College of Pharmacy, Udaipur Page 57

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER-6

HOMEOPATHIC TREATMENT OF
NEURODEGENERATIVE DISEASE

Sunrise College of Pharmacy, Udaipur Page 58

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

HOMEOPATIC TREATMENT OF NEURODEGENERATIVE DISEASE:

6.1 INTRODUCTION: -

Homeopathy is a natural and holistic system of medicine that focuses on stimulating the body’s
self-healing ability. Developed by German physician Samuel Hahnemann in the late 18th
century, homeopathy is based on the principle of "like cures like," where substances that
produce symptoms in healthy individuals are used in diluted forms to treat similar symptoms
in the sick. This gentle form of treatment uses minimal doses and a single remedy tailored to
each individual's condition, aiming to restore balance and promote overall well-being.

6.1.1 Principles of Homeopathic Treatment :

Homeopathy is based on the idea of “like cures like” (similia similibus curentur), meaning a
substance causing symptoms in a healthy person can help heal similar symptoms in a sick
person when given in very small doses. German doctor Samuel Hahnemann developed this
system after testing various substances on himself and others.

Three Main Principles:

➢ Similarity principle: -

Illness symptoms are the body’s response to restore balance. Giving small doses of a substance
that causes similar symptoms in healthy people can trigger the body’s natural healing.

➢ Single Remedy: -

Only one medicine is used at a time, chosen to match the patient’s specific symptoms, to avoid
confusion and interference between multiple drugs.

➢ Minimum Dose: -

Extremely small, diluted doses are used to stimulate healing without side effects or toxicity,
especially helpful for sensitive or weak patients.55

6.2 Medications: -

Sunrise College of Pharmacy, Udaipur Page 59

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Some important medicines are discussed below

6.2.1 Licorice Glycyrrhiza glabra L.:-

Licorice (Glycyrrhiza glabra L.) is a medicinal herb gaining attention for its effectiveness and
safety in treating neurological disorders like ischemic stroke, Alzheimer's, and Parkinson's
disease. Its therapeutic effects are linked to antioxidant, anti-inflammatory, and HMGB-
inhibitory properties. licorice and its active compounds—especially glycyrrhizic acid—as
promising agents for managing neurodegeneration and reducing brain tissue damage.

Licorice root has long been used in food, tobacco, and traditional medicine. It contains active
compounds like flavonoids, isoflavonoids, and triterpenes (such as glycyrrhizic acid) that have
antioxidant, anti-inflammatory, antimicrobial, and even anti-cancer properties. These
compounds also show promise in protecting the brain from damage caused by conditions like
stroke, Alzheimer’s, and Parkinson’s disease.

Licorice affects brain health by influencing key enzymes like MAO-A, MAO-B, and
acetylcholinesterase, which are involved in neurotransmitter regulation. Studies have shown
that licorice can inhibit these enzymes and support brain function. Both its extract and
individual compounds have demonstrated neuroprotective effects by targeting various
pathways involved in nerve damage and degeneration.

[Link] Figure: - Schematic illustration of the effects of licorice on neural disorders.

Sunrise College of Pharmacy, Udaipur Page 60

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

[Link] Neuroprotective Effects of Licorice –

Ischemic Stroke: -

• Licorice compound glabridin reduces oxidative stress and prevents apoptosis.

• GA (Glycyrrhizic acid) regulates microglia and astrocyte activation.

• Inhibits HMGB1-TLR4-IL-17A pathway, reducing inflammation.

• Prevents neuronal ferroptosis via HMGB1/GPX4 signaling.

Alzheimer’s Disease (AD): -

• GA inhibits NF-κB and reduces inflammatory cytokines.

• Protects neurons from glutamate-induced apoptosis.

• Enhances PI3K/Akt and ERK pathways for cell survival.

• ISL (Isoliquiritigenin) reduces ROS and mitochondrial injury.

• Improves memory and cognitive function in animal studies.

• Shows anticholinesterase activity, beneficial in AD treatment.

Parkinson’s Disease (PD)

• ISL reduces ROS and apoptotic markers in dopaminergic neurons.

• Prevents α-synuclein aggregation and promotes disaggregation.

• GA and 18β-Glycyrrhetinic acid increase antioxidant levels.

• Inhibits mitochondrial damage and MEK-ERK-1/2 pathway.

• Improves motor and cognitive symptoms in PD models.

Traumatic Brain Injury (TBI)

• GA suppresses HMGB1 translocation, maintaining BBB integrity.

• Reduces brain edema, apoptosis, and improves motor skills.

• Modulates microglial polarization (promotes M2, inhibits M1).

• Decreases inflammatory cytokines and improves cognition.

• May be effective in diffuse axonal injury and long-term memory support. 56

Sunrise College of Pharmacy, Udaipur Page 61

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

[Link] Figure 5. The cellular processes behind the neuroprotective properties of glycyrrhizin.
Glycyrrhizin may enhance the integrity of the blood-brain barrier by preventing astrogliosis,
neuronal apoptosis, microglia activation, oxidative-induced cellular damage, and
mitochondrial dysfunction. These methods enable glycyrrhizin to boost anti-excitotoxicity (for
epilepsy treatment), decreasing axonal damage and brain edema (TBI improvement), cognitive
and motor function improving (AD and PD treatment), and reducing demyelination (MS
treatment). MS, multiple sclerosis; TBI, traumatic brain injury; PD, Parkinson; AD,
Alzheimer’s disease.56

Sunrise College of Pharmacy, Udaipur Page 62

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

6.2.3 Galanthus woronowii : -

Bioactive alkaloids derived from Galanthus woronowii have shown significant therapeutic
potential for the treatment of Alzheimer’s disease (AD), primarily due to their neuroprotective
effects and enzyme-inhibitory activities. AD is a progressive neurodegenerative disorder
characterized by hallmark features such as the accumulation of amyloid-beta (Aβ) plaques, the
formation of neurofibrillary tangles, and synaptic dysfunction.

Among the alkaloids isolated from Galanthus species, galantamine is particularly notable for
its ability to inhibit acetylcholinesterase (AChE)—the enzyme responsible for the breakdown
of acetylcholine, a neurotransmitter crucial for learning and memory. By inhibiting AChE,
galantamine increases acetylcholine levels in the brain, thereby enhancing synaptic
transmission and cognitive performance. This mechanism offers symptomatic relief and helps
mitigate the cognitive decline associated with AD. Additionally, galantamine acts as an
allosteric modulator of nicotinic acetylcholine receptors, which may further support synaptic
plasticity and improve cognitive outcomes in AD patients.

Beyond their cholinergic effects, Galanthus woronowii alkaloids exhibit neuroprotective

properties by modulating oxidative stress and interfering with Aβ aggregation, both of which
play central roles in AD pathology. These alkaloids may reduce the production or aggregation
of Aβ by interacting with the amyloid precursor protein (APP) or inhibiting beta-secretase
(BACE1), a key enzyme involved in Aβ generation. Such actions could potentially decrease
amyloid plaque formation, thereby slowing disease progression.

Furthermore, the antioxidant capabilities of these alkaloids enable them to scavenge reactive
oxygen species (ROS), thereby mitigating oxidative stress—a major contributor to neuronal
damage in AD. Their anti-inflammatory properties may also help regulate microglial activation
and reduce neuroinflammation, another critical pathological component of AD.

Despite these promising findings, several challenges must be addressed before these alkaloids
can be fully developed as therapeutic agents. A primary concern is their ability to effectively
cross the blood-brain barrier (BBB) and achieve adequate bioavailability within the central
nervous system (CNS). Although galantamine has demonstrated CNS penetration, further
research is needed to optimize the pharmacokinetic properties of these compounds to enhance

Sunrise College of Pharmacy, Udaipur Page 63

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

BBB permeability. Moreover, ensuring target specificity and minimizing off-target effects are
essential for maximizing therapeutic efficacy while reducing potential adverse effects.

In summary, alkaloids from Galanthus woronowii, especially galantamine, offer a multifaceted

approach to AD treatment by combining cholinergic enhancement, neuroprotection, anti-
oxidative, and anti-inflammatory actions. Continued research into their pharmacodynamics and
pharmacokinetics will be crucial to fully realize their potential as effective treatments for
Alzheimer’s disease. 57

Galanthus woronowii is a species of Galanthus. It’s a snowdrop from the Caucasus.

Galantamine is a pure, unadulterated Galanthus extract. According to a recent study,
galantamine appears to slow the progression of neurodegenerative diseases. It also inhibits
acetylcholine in a reversible and competitive manner. Galantamine reduces AChE synthesis
while enhancing the brain’s response to AChE. In one study, galantamine was found to reduce
functional ability and cognition decline in 653 Alzheimer’s patients with mild to moderate
Alzheimer’s disease. 58

Sunrise College of Pharmacy, Udaipur Page 64

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CHAPTER 7
CONCLUSION

Sunrise College of Pharmacy, Udaipur Page 65

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

CONCLUSION: -

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD),

and Amyotrophic Lateral Sclerosis (ALS), represent a major challenge in modern medicine due
to their progressive and often irreversible nature. Through this review, we explored the complex
pathophysiology underlying these diseases, identifying genetic, environmental, and age-related
factors as key contributors to disease onset and progression. While the clinical manifestations
of these diseases differ—ranging from cognitive decline in Alzheimer's to motor dysfunction
in Parkinson's and muscle weakness in ALS—they share common mechanisms such as protein
misfolding, oxidative stress, mitochondrial dysfunction, and neuroinflammation.

Diagnosis of these diseases remains reliant on a combination of clinical evaluation, imaging

techniques, and biomarker analysis, but early detection continues to be a challenge due to
overlapping symptoms and the absence of definitive diagnostic tests. Current treatment
strategies focus on symptomatic relief and slowing disease progression rather than curing the
underlying pathology. Pharmacological options, including cholinesterase inhibitors for AD,
dopaminergic drugs for PD, and riluzole for ALS, have shown limited efficacy in halting
disease progression.

Importantly, this review also explored alternative treatment approaches, including homeopathic
and Ayurvedic remedies, which aim to improve patient quality of life through natural
compounds, dietary adjustments, and mind-body practices. Ayurvedic herbs such as Brahmi
(Bacopa monnieri), Ashwagandha (Withania somnifera), and Turmeric (Curcuma longa) have
shown potential in reducing oxidative stress and inflammation, while homeopathic treatments
are often tailored to individual symptom patterns. Although these alternative therapies lack
large-scale clinical validation, they hold promise as adjunct therapies alongside conventional
treatments.

In conclusion, while significant progress has been made in understanding the molecular and
clinical basis of neurodegenerative diseases, effective disease-modifying treatments remain
elusive. Future research should focus on early diagnostic biomarkers, novel drug targets, and
the integration of traditional and modern medicine to develop holistic, patient-centered
therapeutic strategies. A multidisciplinary approach combining advanced molecular research,
innovative drug development, and personalized medicine may pave the way for more effective
management of these devastating disorders.

Sunrise College of Pharmacy, Udaipur Page 66

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Chapter 8
References

Sunrise College of Pharmacy, Udaipur Page 67

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

1. Wolfe, M. S. (2018) Molecular and cellular basis of neurodegenerative diseases, pp. 7-

36. London: Academic Press.

2. Dugger, B.N. and Dickson, D.W., 2017. Pathology of neurodegenerative diseases. Cold
Spring Harbor Perspectives in Biology, Advance Publication, 6 January.

3. Armstrong, R., 2020. What causes neurodegenerative disease? Folia Neuropathologica,

58(2), pp.93-112.

4. Emerit, J., Edeas, M., & Bricaire, F. (2004). Neurodegenerative diseases and oxidative
stress. Biomedicine & Pharmacotherapy, 58(1), 39-46.

5. evenson, R.W., Sturm, V.E., and Haase, C.M., 2014. Emotional and behavioral
symptoms in neurodegenerative disease: A model for studying the neural bases of
psychopathology. Annual Review of Clinical Psychology, 10.

6. Saba, L. (ed.) (2015) Imaging in the Neurodegenerative Disorders. Sections 3-5

Oxford: Oxford University Press.

7. Szymański, P., Markowicz, M., Janik, A., Ciesielski, M. & Mikiciuk-Olasik, E. (2010)
‘Neuroimaging diagnosis in neurodegenerative diseases’, Nuclear Medicine Review.

8. Durães, F., Pinto, M., & Sousa, E. (2018) ‘Old drugs as new treatments for
neurodegenerative diseases’, Pharmaceuticals, 11(2), p. 44.

9. Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J.
(2022) ‘A review of the common neurodegenerative disorders: Current therapeutic
approaches and the potential role of nanotherapeutics’, International Journal of
Molecular Sciences, 23(3), p. 1851

10. Shukla, A. K., Nilgirwar, P. S. & Bali, S. D. (2025) ‘Current pharmacological treatments
for neurodegenerative diseases’, in The Neurodegeneration Revolution: Emerging
Therapies and Sustainable Solutions, pp. 117–126.

11. Poddar, Mrinal K., Apala Chakraborty, and Soumyabrata Banerjee. 2021.
Neurodegeneration: Diagnosis, Prevention, and Therapy.

12. Blennow, K., de Leon, M.J. and Zetterberg, H., 2006. Alzheimer's disease. The Lancet,
368(9533), pp. 387-403

Sunrise College of Pharmacy, Udaipur Page 68

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

13. Cherry, K. (2024) "What is Alzheimer’s disease? Learn about causes, treatments, and
prevention of Alzheimer's," Verywell Mind, 5 October.

14. Breijyeh, Z. and Karaman, R. (2020) “Comprehensive review on Alzheimer’s disease:

Causes and treatment,” Molecules, 25(24), p. 5789.

15. Shah, R.S., Lee, H.G., Xiongwei, Z., Perry, G., Smith, M.A. and Castellani, R.J. (2008)
“Current approaches in the treatment of Alzheimer’s disease,” Biomedicine &
Pharmacotherapy, 62(4), pp. 199–207.

16. Teipel, S., Gustafson, D., Ossenkoppele, R., Hansson, O., Babiloni, C., Wagner, M.,
Riedel-Heller, S.G., Kilimann, I. and Tang, Y. (2022) 'Alzheimer disease: Standard of
diagnosis, treatment, care, and prevention', Journal of Nuclear Medicine, 63(7), pp.
981-985.

17. Reve, B., Moser, M.-B., Moser, E. and Doeller, C., 2017. Starting in Norway, a new
approach to Alzheimer's. World Economic Forum.

18. Mehta, A., 2012. Alzheimer's Disease and Dementia Tomorrow. [Link].

19. Marsden, C.D., 1994. Parkinson's disease. Journal of Neurology, Neurosurgery, and
Psychiatry, 57(6), pp.672–681

20. Cincotta, M.C., 2023. Newly Diagnosed With Parkinson’s Disease? Here’s What You
Need to Know. Temple Health.

21. Kapur, S.S., Eske, J. and Medical News Today, 2023. 13 early signs of Parkinson’s
disease. Healthline and Medical News Today.

22. Shafique, H., Blagrove, A., Chung, A. and Logendrarajah, R., 2011. Causes of
Parkinson’s disease: Literature review. Journal of Parkinsonism and Restless Legs
Syndrome, 1(1), pp.5-7.

23. Gray, P. and Hildebrand, K., 2000. Fall risk factors in Parkinson’s disease. Journal of
Neuroscience Nursing, 32(4), pp.222-228.

24. Doherty, C. and Patel, S. (2024) ‘How to prevent Parkinson’s disease: Diet and exercise
may play key roles’, Verywell Health, 4 June.

Sunrise College of Pharmacy, Udaipur Page 69

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

25. Pagano, G., Niccolini, F. and Politis, M. (2016) 'Imaging in Parkinson’s disease',
Clinical Medicine, 16(4), pp. 371–377.

26. Gaillard, F., Sharma, R., Sciacca, F., et al. (2025) 'Parkinson disease', [Link].

27. Eusebi, P., Giannandrea, D., Biscetti, L., Abraha, I., Chiasserini, D., Orso, M.,
Calabresi, P. and Parnetti, L. (2017) 'Diagnostic utility of cerebrospinal fluid α-
synuclein in Parkinson's disease: A systematic review and meta-analysis', Movement
Disorders, 32(9), pp. 1389–1400.

28. Zahoor, I., Shafi, A. & Haq, E., 2020. Pharmacological treatment of Parkinson’s
disease. In: Parkinson’s Disease: Pathogenesis and Clinical Aspects.

29. Goldenberg, M.M., 2008. Medical management of Parkinson’s disease. Pharmacy and
Therapeutics, 33(10), pp.590–594, 599–606.

30. Kobylecki, C.A., 2020. Update on the diagnosis and management of Parkinson's
disease. Clinical Medicine, 20(4), pp.393-398.

31. Dorsey, E. R. (2020) ‘The rise of Parkinson’s disease’, American Scientist, 108(3), p.
176.

32. Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2020) Ending Parkinson’s
Disease: A Prescription for Action. New York: Public Affairs.

33. Shin, D.S., Pratt, A.J., Getzoff, E.D. and Perry, J.J.P., 2010. Amyotrophic lateral
sclerosis. Advanced Understanding of Neurodegenerative Diseases. pp.418-428

34. Lights, V. and Guthrie, C., 2023. Amyotrophic lateral sclerosis (ALS). Medically
reviewed by Moawad, H., M.D. Updated on December 18, 2023. Healthline.

35. LeBrun, N. and Metrus, N.R., MD (2023) ‘9 Early Signs of ALS’, Verywell Health, 22
February.

36. ALS Association (n.d.) ALS genes and mutations.2025

37. Chen, S., Sayana, P., Zhang, X. and Le, W. (2013) 'Genetics of amyotrophic lateral
sclerosis: an update', Molecular Neurodegeneration, 8(28).

38. Perreault, H. (2023) Diagram illustrating the causes and risk factors of Amyotrophic
Lateral Sclerosis (ALS). Physiopedia.

Sunrise College of Pharmacy, Udaipur Page 70

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

39. Ingre, C., Roos, P.M., Piehl, F., Kamel, F. and Fang, F. (2015) ‘Risk factors for
amyotrophic lateral sclerosis’, Clinical Epidemiology, 7(1), pp. 181–193.

40. Ferguson, T.A. and Elman, L.B. (2007) ‘Clinical presentation and diagnosis of
amyotrophic lateral sclerosis’, NeuroRehabilitation, 22(4), pp. 409–416.

41. LeBrun, N. (2023) ‘9 Early Signs of Amyotrophic Lateral Sclerosis (ALS)’, Brain &
Nervous System. Verywell. Updated on 22 February. Medically reviewed by Nicholas
R. Metrus, MD.

42. Wexler, M., 2024. Amyotrophic lateral sclerosis treatment options. Last updated 11
April 2024. Fact-checked by Ines Martins, PhD. ALS News Today

43. Hoxhaj, P., Hastings, N., Kachhadia, M.P., Gupta, R., Sindhu, U., Durve, S.A., Azam,
A., Auz Vinueza, M.J.A., Bhuvan, Win, S.H., Rathod, D.C. and Afsar, A.P., 2023.
Exploring advancements in the treatment of amyotrophic lateral sclerosis: A
comprehensive review of current modalities and future prospects. Cureus, 15(9),
p.e45489.

44. Mehta, P., Kaye, W., Raymond, J., Wu, R., Larson, T., Punjani, R., Heller, D., Cohen,
J., Peters, T., Muravov, O. and Horton, K., 2014. Prevalence of amyotrophic lateral
sclerosis — United States, 2014. Morbidity and Mortality Weekly Report (MMWR),
63(7), pp.1-10.

45. Kapur, M. (2016) Basic Principles of Ayurveda. In: Psychological Perspectives on

Childcare in Indian Indigenous Health Systems. Springer, New Delhi.

46. Jagtap, V., Mandhare, N., Jagtap, A., Galave, V., Phadtare, A. and Kolhe, O. (2021) 'An
overview on principle, diagnosis and treatment of Ayurveda', World Journal of
Pharmaceutical Research, 10(8), pp. 517–553.

47. Dar, N.J. and Ahmad, M., 2020. Neurodegenerative diseases and Withania somnifera
(L.): An update. Journal of Ethnopharmacology, 256, p.112769.

48. Lerose, V., Ponticelli, M., Benedetto, N., Carlucci, V., Lela, L., Tzvetkov, N.T. and
Milella, L. (2024) 'Withania somnifera (L.) Dunal, a potential source of phytochemicals
for treating neurodegenerative diseases: A systematic review', Plants, 13(6), p. 771.

49. Dhanasekaran, M., Holcomb, L.A., Hitt, A.R., Tharakan, B., Porter, J.W., Young, K.A.
and Manyam, B.V. (2009) 'Centella asiatica extract selectively decreases amyloid-β

Sunrise College of Pharmacy, Udaipur Page 71

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

levels in hippocampus of Alzheimer’s disease animal model', Phytotherapy Research,

23, pp. 14–19.

50. Rosyidi, R.M., Rusidi, H.A., Januarman, J., Priyanto, B., Wardhana, D.P.W., Rozikin,
R., Wahyudi, W. and Baskoro, W. (2024) ‘Centella asiatica effect on traumatic brain
injury: A systematic review’, Surgical Neurology International, 15, p. 248.

51. Gray, N.E., Zweig, J.A., Murchison, C., Caruso, M., Matthews, D.G., Kawamoto, C.,
Harris, C.J., Quinn, J.F. and Soumyanath, A. (2017) 'Centella asiatica attenuates Aβ-
induced neurodegenerative spine loss and dendritic simplification', Neuroscience
Letters, 646, pp. 24–29.

52. Manjunatha, B., Roy, U.B. & Keshamma, E. (2025) ‘A review on therapeutic properties
of Centella asiatica and future perspectives’, International Journal of Creative
Research Thoughts (IJCRT), 13(3), pp. ISSN: 2320-2882.

53. Wahab, M.Z.A., Zakaria, F.N., Noor, H.S.M., Abidin, M.Z.Z., Hashim, N.K., Dasiman,
R., Ismail, N.H. & Amom, Z. (2021) ‘Exploring neuroprotective properties of Centella
asiatica extract on metabolic change in chronic stress-induced rats’, KnE Life Sciences,
The 4th International Virtual Conference on Nursing, pp. 940–952.

54. Wong, J.H., Barron, A.M. and Abdullah, J.M., 2021. Mitoprotective effects of Centella
asiatica (L.) Urb.: Anti-inflammatory and neuroprotective opportunities in
neurodegenerative disease. Frontiers in Pharmacology, 12, p.687935.

55. Evereklioğlu, C. and Erten, M., eds., 2022. Current Research in Health Sciences. March
ed. Gece Kitaplığı.

56. Zulfugarova, P., Zivari-Ghader, T., Maharramova, S., Ahmadian, E., Eftekhari, A.,
Khalilov, R., Turksoy, V.A., Rosić, G. and Selakovic, D., 2023. A mechanistic review
of pharmacological activities of homeopathic medicine licorice against neural diseases.
Frontiers in Neuroscience, 17, p.1148258.

57. Arumugam, P., 2024. Investigating the neuroprotective effects of alkaloids from
Galanthus woronowii as a potential treatment for Alzheimer’s disease.

58. Ara, I., Maqbool, M. and Gani, I. (2022). Neuroprotective Activity of Herbal Medicinal
Products: A Review. International Journal of Current Research in Physiology and
Pharmacology, 6(4), pp.1–10.

Sunrise College of Pharmacy, Udaipur Page 72

[Link]. VIITH Sem. Neurodegenerative Disease (A Progressive Disorder)

Sunrise College of Pharmacy, Udaipur Page 73